From $20K to $1.8B in revenue: how one founder built a telehealth giant with AI and no VC
What's the deal? Matthew GallagherDealroom has a profile for this one. Try Dealroom →, a 41-year-old entrepreneur in Los Angeles, built Medvi — a telehealth company selling compounded GLP-1 weight-loss drugs — with $20,000, more than a dozen AI tools, and one employee: his brother. In its first full year, 2025, the company generated $401 million in revenue and $65 million in net profit, a 16.2% margin. It is now on track for $1.8 billion in sales in 2026, generating more than $3 million per day. Medvi has raised no outside funding.
Gallagher usedChatGPT, ClaudeDealroom has a profile for this one. Try Dealroom →, GrokDealroom has a profile for this one. Try Dealroom →, Midjourney, and Runway to build the platform, write code, generate ads, and handle customer service. Two infrastructure partners — CareValidateDealroom has a profile for this one. Try Dealroom → and OpenLoop HealthDealroom has a profile for this one. Try Dealroom → — manage physicians, prescriptions, pharmacies, and compliance. Medvi owns the customer relationship and charges as little as $179 for a first month's supply of drugs.
Why now? Gallagher launched in September 2024, perfectly timed to a surge in demand for cheap, online GLP-1 prescriptions. His 16.2% net margin compares starkly to Hims & Hers' 5.5% on $2.4 billion in revenue with 2,442 employees. Total profits so far stand at $70–80 million, which Gallagher is routing largely through a foundation he established with an initial $1 million donation.
Men's health launched in February 2026 and signed 50,000 customers in its first month, with Gallagher projecting it will eclipse the GLP-1 business within four months. Meal delivery launched in March; women's health, hair growth, and skincare are next.
What could go wrong? Quite a lot. The FDA issued Medvi a formal warning letter in February 2026 for misleading product claims, and declared the semaglutide shortage — the legal basis for compounded GLP-1 prescriptions — resolved in February 2025. That window may be closing, and enforcement is accelerating: the agency has sent more than 70 warning letters to similar telehealth companies in the preceding six months.
A security researcher discovered a serious data vulnerability in March 2026: sequential, unprotected URLs exposed the personal health records of all 250,000 Medvi patients with no authentication required. The fix took 90 minutes. HIPAA breach notification requirements — covering patient notification, federal reporting, and media disclosure — appear not to have been followed, with potential penalties reaching $1.9 million annually for willful neglect. Hundreds of Medvi Facebook ads were also reportedly running under accounts impersonating doctors, raising Federal Trade Commission concerns.
Medvi holds no proprietary technology, physician network, or exclusive supplier relationships. Any operator with marketing skills and access to CareValidate or OpenLoop can replicate the model.
The signal: Medvi is the most concrete proof yet of what Sam AltmanDealroom has a profile for this one. Try Dealroom → predicted: a near-one-person company approaching $1 billion in revenue, made possible entirely by AI. For the broader startup ecosystem, it is less a blueprint than a stress test — showing what AI-enabled execution can achieve, and exactly how fast regulatory and competitive exposure can accumulate when you move that quickly with that few safeguards.
Sources:
The NY Times
Forbes
A.M.
